Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is well-positioned for future growth, with anticipated steady performance from its core franchises, including Eylea, Dupixent, and Libtayo, supported by expansion across various indications and regions. Revenue projections for 2025-2027 have been adjusted upward, reflecting increased estimates primarily driven by Dupixent, with EPS forecasts also showing significant growth over the same period. Furthermore, the company maintains a robust balance sheet and a strong pipeline in oncology, neurology, and cardiometabolics, which are expected to create additional growth opportunities, reinforcing a positive long-term outlook.

Regeneron Pharmaceuticals faces a decline in demand for its EYLEA product, projected to decrease approximately 10% sequentially in the latter half of the year due to competition from biosimilars and Roche's Vabysmo, which could compromise revenue stability. Additionally, the company's development pipeline is under intense competition, raising concerns about the potential for revenue generation and the likelihood of new products receiving approval from the FDA. Furthermore, underperformance of key medications like Dupixent and Libtayo could lead to disappointing financial results, thereby negatively impacting Regeneron's long-term revenue outlook and overall market confidence.